FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211253141> ?p ?o ?g. }

• W4211253141 endingPage "18" @default.
• W4211253141 startingPage "9" @default.
• W4211253141 abstract "CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC504.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investigated the efficacy and safety of CR1447 for patients with metastatic estrogen receptor-positive (A) and AR-positive triple-negative breast cancers (B).(A) included patients with at most one prior endocrine therapy line without progression ≥6 months, whereas (B) included patients with ≤2 prior chemotherapy lines, all displaying advanced signs of disease. The primary endpoint was disease control at week 24 (DC24). The null hypothesis was DC24 ≤30% (A) and ≤15% (B). Thirty-seven patients were recruited (29 in (A) and 8 in (B)); accrual was stopped following an interim analysis demonstrating futility in (A) and slow accrual in (B).DC24 was attained in 5/21 (95% CI: 8.2-47.2) patients in (A) and none in (B). The median progression-free survival was 5.1 months (95% CI: 2.5-5.6) in (A) and 2.5 months (95% CI: 0.7-2.6) in (B). The median overall survival was 24.6 months (95% CI: 22.9-not applicable) in (A) and 10.8 months (95% CI: 3.3-10.9) in (B). CR1447 had a favorable safety profile without treatment-related grade 3-5 toxicities in (A). Especially no side effects linked to androgenic effects were observed.Despite this trial being negative, the 24% DC24 rate in a second-line setting, and the prolonged partial response experienced by a patient, indicate activity. Further evaluation of CR1447 in endocrine-sensitive patients or combination trials appears warranted." @default.
• W4211253141 created "2022-02-13" @default.
• W4211253141 creator A5004165533 @default.
• W4211253141 creator A5005951305 @default.
• W4211253141 creator A5014892721 @default.
• W4211253141 creator A5022994319 @default.
• W4211253141 creator A5024058623 @default.
• W4211253141 creator A5025804381 @default.
• W4211253141 creator A5031581462 @default.
• W4211253141 creator A5041795237 @default.
• W4211253141 creator A5049232435 @default.
• W4211253141 creator A5061285912 @default.
• W4211253141 creator A5062681986 @default.
• W4211253141 creator A5083340638 @default.
• W4211253141 creator A5091137864 @default.
• W4211253141 date "2022-03-01" @default.
• W4211253141 modified "2023-10-13" @default.
• W4211253141 title "SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients" @default.
• W4211253141 cites W108148244 @default.
• W4211253141 cites W1464936406 @default.
• W4211253141 cites W1885639867 @default.
• W4211253141 cites W1916572113 @default.
• W4211253141 cites W1966987047 @default.
• W4211253141 cites W1984262137 @default.
• W4211253141 cites W1984535299 @default.
• W4211253141 cites W2001340750 @default.
• W4211253141 cites W2011254773 @default.
• W4211253141 cites W2026245063 @default.
• W4211253141 cites W2026430211 @default.
• W4211253141 cites W2034766336 @default.
• W4211253141 cites W2037066085 @default.
• W4211253141 cites W2040732378 @default.
• W4211253141 cites W2040935785 @default.
• W4211253141 cites W2073367400 @default.
• W4211253141 cites W2081491080 @default.
• W4211253141 cites W2101403785 @default.
• W4211253141 cites W2104801251 @default.
• W4211253141 cites W2113110366 @default.
• W4211253141 cites W2125094267 @default.
• W4211253141 cites W2138475890 @default.
• W4211253141 cites W2139712038 @default.
• W4211253141 cites W2151082560 @default.
• W4211253141 cites W2157375575 @default.
• W4211253141 cites W2158997529 @default.
• W4211253141 cites W2167243645 @default.
• W4211253141 cites W2295971206 @default.
• W4211253141 cites W2405807584 @default.
• W4211253141 cites W2430731787 @default.
• W4211253141 cites W2528767298 @default.
• W4211253141 cites W2560409587 @default.
• W4211253141 cites W2617437931 @default.
• W4211253141 cites W2620993107 @default.
• W4211253141 cites W2621271973 @default.
• W4211253141 cites W2750544551 @default.
• W4211253141 cites W2767600184 @default.
• W4211253141 cites W2784775153 @default.
• W4211253141 cites W2805575723 @default.
• W4211253141 cites W2896846857 @default.
• W4211253141 cites W2897422388 @default.
• W4211253141 cites W2921910774 @default.
• W4211253141 cites W2946370795 @default.
• W4211253141 cites W2946659976 @default.
• W4211253141 cites W2948069739 @default.
• W4211253141 cites W2950164932 @default.
• W4211253141 cites W2979389583 @default.
• W4211253141 cites W3082818078 @default.
• W4211253141 cites W4241664300 @default.
• W4211253141 doi "https://doi.org/10.1530/eo-21-0009" @default.
• W4211253141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37435469" @default.
• W4211253141 hasPublicationYear "2022" @default.
• W4211253141 type Work @default.
• W4211253141 citedByCount "0" @default.
• W4211253141 crossrefType "journal-article" @default.
• W4211253141 hasAuthorship W4211253141A5004165533 @default.
• W4211253141 hasAuthorship W4211253141A5005951305 @default.
• W4211253141 hasAuthorship W4211253141A5014892721 @default.
• W4211253141 hasAuthorship W4211253141A5022994319 @default.
• W4211253141 hasAuthorship W4211253141A5024058623 @default.
• W4211253141 hasAuthorship W4211253141A5025804381 @default.
• W4211253141 hasAuthorship W4211253141A5031581462 @default.
• W4211253141 hasAuthorship W4211253141A5041795237 @default.
• W4211253141 hasAuthorship W4211253141A5049232435 @default.
• W4211253141 hasAuthorship W4211253141A5061285912 @default.
• W4211253141 hasAuthorship W4211253141A5062681986 @default.
• W4211253141 hasAuthorship W4211253141A5083340638 @default.
• W4211253141 hasAuthorship W4211253141A5091137864 @default.
• W4211253141 hasBestOaLocation W42112531411 @default.
• W4211253141 hasConcept C121608353 @default.
• W4211253141 hasConcept C126322002 @default.
• W4211253141 hasConcept C143998085 @default.
• W4211253141 hasConcept C168563851 @default.
• W4211253141 hasConcept C203092338 @default.
• W4211253141 hasConcept C205679159 @default.
• W4211253141 hasConcept C2775930923 @default.
• W4211253141 hasConcept C2777909004 @default.
• W4211253141 hasConcept C526805850 @default.
• W4211253141 hasConcept C530470458 @default.
• W4211253141 hasConcept C61943457 @default.

• next